HROW

Harrow, Inc. operates as a pharmaceutical company focused on ophthalmology, providing a range of eye care products primarily to healthcare professionals and patients. Headquartered in Nashville, Tennessee, the company operates through two primary segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. Harrow's compounding business produces customized sterile and non-sterile medications through its network of facilities, serving ophthalmologists and optometrists across the United States. The company manufactures and markets FDA-approved ophthalmic pharmaceutical products, including its proprietary formulations for post-surgical inflammation, eye infections, and other ocular conditions. Key commercial products include ImprimisRx-branded compounded formulations and several approved drug products such as IHEEZO, TRIESENCE, and DEXYCU. Harrow acquired Surface Ophthalmics in 2021 and continues to expand its product portfolio through both organic development and strategic acquisitions. The company employs approximately 400 people and operates multiple compounding pharmacies and manufacturing facilities. Recent strategic initiatives include advancing its pipeline of ophthalmic drug candidates through clinical development and expanding its commercial infrastructure to support growing product sales. Harrow positions itself as a vertically integrated eye care pharmaceutical company, leveraging its compounding expertise and regulatory capabilities to serve the specialized needs of eye care professionals.